Q-omics provides the consensus-scored KRT42P profile across patient tissues and cancer cell-line models. KRT42P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT42P is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, KRT42P RNA expression shows 13,099 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where KRT42P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT42P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT42P survival associations across molecular data types. KRT42P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT42P RNA expression–survival associations across cancer types. High KRT42P expression shows unfavorable associations in KIRC, LIHC, SKCM and DLBC, but favorable associations in LUSC and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT42P RNA expression.
This table summarizes KRT42P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for KRT42P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT42P shows lower tumor expression in LUAD and higher tumor expression in KIRP, HNSC, LUSC, THCA and PAAD. The KIRP box plot shows higher KRT42P RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p < 0.001).
This table shows molecular features associated with KRT42P in patient tissues and cancer cell lines. In patient samples, KRT42P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
